However, NGAL might incorporate a new capacity to early detect and quantify the increased risk posed by the synergistic action of hypertension and diabetes; and, prospectively, also to monitor the evolution and prognosis of CKD patients. The gene discussed is LCN2; the disease is chronic kidney disease.